MMWR: Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants

Nirsevimab continues to show strong protection against severe RSV disease in infants, according to new data from 24 states. CDC analysis found the antibody was 80% effective against RSV-related ICU admission and 83% effective against acute respiratory failure among infants under one, most of whom were previously healthy and born at term.

These findings reinforce the growing evidence that RSV immunization is reducing severe outcomes nationwide. Public health communicators can help reinforce guidance that infants should be protected each RSV season—either through maternal vaccination during pregnancy or infant receipt of long-acting monoclonal antibodies such as nirsevimab or clesrovimab. Read more in CDC’s MMWR here.